3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Sarcoma
6
Ovarian Neoplasms
4
Neurofibrosarcoma
3
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Hemangiosarcoma
2
Dermatofibrosarcoma
2
Vascular Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solitary Fibrous Tumors
1
Solid Tumors
1
Solid Tumor, Adult
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Relapsed Pediatric Solid Tumor
1
Refractory or Recurrent Solid Tumor
1
Osteosarcoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Adipose Tissue
1
Myoepithelioma
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Histiocytoma, Angiomatoid Fibrous
1
Histiocytoma
1
Hemangioendothelioma, Epithelioid
1
Granuloma, Plasma Cell
1
Granular Cell Tumor
1
Glomus Tumor
1
Interventions
spartalizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Refractory or Recurrent Solid Tumor
×
pazopanib
×
Clear all
NCT05210413
2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2
Active not recruiting
80 enrolled